Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044032 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2AKR1C3AKR1C2AKR1C1MAPK1 | |
| SCHEMBL3060050 | 0.89 | HDAC1 (0.52) | — | |
| SCHEMBL3057391 | 0.89 | SMN1; SMN2 (0.47) | SMN1; SMN2AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL13136808 | 0.89 | HDAC1 (0.52) | — | |
| SCHEMBL12317364 | 0.89 | HDAC1 (0.52) | — | |
| SCHEMBL12317390 | 0.87 | SMN1; SMN2 (0.45) | SMN1; SMN2 | |
| SCHEMBL12317391 | 0.86 | SMN1; SMN2 (0.45) | SMN1; SMN2AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6863097 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL4536390 | 0.83 | MAPK1 (0.45) | MAPK1 | |
| SCHEMBL12340683 | 0.83 | MEN1 (0.45) | SMN1; SMN2AKR1C3AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476255-B2 | Histone deacetylase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-07-02 | — | — | US | disclosed |
| US-8476255-B2 | Histone deacetylase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-07-02 | — | — | US | disclosed |
| US-20100222379-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| US-20100222379-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| WO-2009047615-A2 | NOVEL HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222379-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | HDAC5, HDAC2, HDAC1 | SMN1; SMN2 4066/4885AKR1C3 520/4885AKR1C2 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.